PeptiDream Strengthens Executive Leadership Team with Three New Executive Vice Presidents to Accelerate Global Growth
PeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kawasaki, Japan, has announced the appointment of three new Executive Vice Presidents as part of its ongoing effort to strengthen its leadership team and accelerate its transformation into a fully integrated global discovery and development organization. The appointments reflect the company’s strategic focus on expanding its operational capabilities, advancing its growing clinical pipeline, and positioning itself for long-term international growth in the highly competitive biopharmaceutical industry.
The newly appointed executives will oversee key functional areas that are critical to PeptiDream’s continued evolution, including operations, corporate strategy, and people and culture. Together, they bring decades of experience across pharmaceutical research and development, commercial operations, business development, global strategy, organizational leadership, and human resources.
According to the company, these appointments are intended to reinforce operational excellence while enhancing cross-functional collaboration and strengthening the execution of its research, development, and commercialization objectives. As PeptiDream continues to expand its portfolio of peptide-based therapeutics and deepen collaborations with global pharmaceutical partners, experienced leadership will play a vital role in supporting the company’s next stage of growth.
Supporting PeptiDream’s Global Transformation
Over the past several years, PeptiDream has evolved from a discovery-focused biotechnology company into a rapidly growing biopharmaceutical organization with expanding clinical development activities and an increasingly international presence.
The company has built its reputation through its proprietary peptide discovery platform, which has enabled the identification and development of novel peptide therapeutics across multiple disease areas. In addition to advancing its own internal pipeline, PeptiDream has established numerous strategic collaborations with leading global pharmaceutical companies seeking to leverage its technology for drug discovery and development.
As the organization continues to mature, its operational requirements have expanded significantly. Managing larger development programs, supporting global partnerships, coordinating international operations, and preparing for future commercialization require leadership with extensive experience across multiple aspects of the pharmaceutical value chain.
The appointment of three seasoned executives reflects PeptiDream’s recognition that organizational capabilities must continue evolving alongside scientific innovation.
CEO Highlights Strategic Importance of New Leadership
Patrick C. Reid, Ph.D., President and Chief Executive Officer of PeptiDream, welcomed the appointments and emphasized the important role the new executives will play in supporting the company’s long-term strategy.
According to Dr. Reid, each of the newly appointed Executive Vice Presidents brings exceptional expertise and proven leadership experience that aligns closely with PeptiDream’s strategic priorities.
He noted that strengthening the executive leadership team will enhance the company’s ability to execute efficiently, scale its global operations, and maintain momentum across its expanding clinical pipeline.
Dr. Reid also explained that these appointments support the company’s ongoing transformation into a global discovery and development organization capable of delivering innovative therapies to patients worldwide while creating sustainable long-term value for shareholders, partners, and other stakeholders.
The expanded leadership team is expected to contribute significantly to improving operational effectiveness as PeptiDream continues broadening both its scientific capabilities and commercial ambitions.
Catherine Ohura Named Executive Vice President of Operations
Among the three appointments, Catherine Ohura has been named Executive Vice President responsible for Operations.
Ohura brings extensive leadership experience gained across several internationally recognized life sciences and healthcare organizations.
Prior to joining PeptiDream, she served as Representative Director and General Manager of Illumina Japan, where she led business expansion efforts for the company’s portfolio of genomic technologies, including next-generation sequencing platforms and related services.
During her tenure, she played a central role in growing Illumina’s presence within the Japanese market while supporting the broader adoption of genomic technologies across healthcare and life science research.
Before joining Illumina, Ohura served as Representative Director and General Manager of Labcorp Laboratories Japan, where she gained additional experience managing complex healthcare operations and diagnostic services.
Her leadership background also includes serving as Chief Executive Officer of the Global Health Innovative Technology (GHIT) Fund, an organization dedicated to fostering international public-private partnerships focused on addressing global health challenges.
Through her work with GHIT, she contributed to collaborative initiatives involving governments, nonprofit organizations, academic institutions, and private-sector partners working together to develop innovative healthcare solutions for underserved populations.
Earlier in her career, Ohura held multiple leadership positions at Bristol Myers Squibb, working both at the company’s global headquarters in the United States and within its Japanese affiliate.
Her experience spans both research and development as well as commercial operations, providing her with a broad understanding of the pharmaceutical industry from scientific innovation through product commercialization.
In addition to her executive responsibilities, she currently serves as an External Director of Sugi Holdings Co., Ltd., further demonstrating her extensive governance and corporate leadership experience.
At PeptiDream, Ohura will oversee operational functions designed to support the company’s expanding research, development, and business activities as it continues growing internationally.
Jun Kono Appointed Executive Vice President of Strategy
PeptiDream has also appointed Jun Kono as Executive Vice President responsible for Strategy.
Kono joins the company with an extensive background in corporate strategy, business development, commercial leadership, and global pharmaceutical operations accumulated through years of experience at Astellas Pharma.
Most recently, he served as Japan Commercial Head, where he directed commercial strategy and operations within one of the company’s largest and most strategically important markets.
His responsibilities included overseeing commercial execution while supporting continued business growth within Japan’s highly competitive pharmaceutical sector.
Prior to leading commercial operations in Japan, Kono held numerous senior leadership positions based in both the United States and Europe.
These international assignments provided him with significant experience managing regional operations while contributing to broader global business initiatives.
His career has also included leadership of business development activities aimed at shaping research and development portfolios through strategic licensing, partnerships, and corporate growth initiatives.
This combination of strategic planning, commercial expertise, portfolio management, and international operational leadership provides PeptiDream with valuable capabilities as the company seeks to expand its presence across global pharmaceutical markets.
Kono also possesses a strong academic foundation in business leadership, having earned his Master of Business Administration degree with honors from the University of Chicago Booth School of Business, one of the world’s leading graduate business institutions.
Within his new role, he is expected to help guide corporate strategy, identify new growth opportunities, strengthen global partnerships, and support long-term business expansion initiatives.
Kodo Shikata to Lead People and Culture
The third executive appointment is Kodo Shikata, Ph.D., who has been named Executive Vice President responsible for People and Culture.
Shikata brings a distinctive combination of scientific expertise and human resources leadership that reflects the increasingly multidisciplinary nature of leadership within modern biotechnology organizations.
Most recently, he served as Head of Global Human Resources Strategy at Eisai, where he led enterprise-wide initiatives focused on organizational effectiveness, workforce development, leadership capability, and global talent management.
His responsibilities included designing strategies to strengthen corporate culture while supporting the company’s evolving global workforce.
Unlike many HR executives, Shikata began his professional career as a research scientist.
He previously worked as a Principal Scientist within Eisai Product Creation Systems in the Neurology Unit at the company’s research laboratory in London.
This scientific background provides him with firsthand understanding of the needs and challenges faced by research organizations, enabling him to develop talent strategies that align closely with scientific innovation.
Shikata holds a Doctor of Philosophy degree in medicine from the Okayama University Graduate School of Medicine, further strengthening his ability to bridge scientific excellence with organizational leadership.
At PeptiDream, he will oversee initiatives related to talent acquisition, leadership development, organizational culture, employee engagement, and workforce strategy as the company continues expanding internationally.
Diverse Leadership Experience Across the Pharmaceutical Industry
Collectively, the three newly appointed Executive Vice Presidents contribute an exceptionally broad range of expertise spanning nearly every stage of pharmaceutical innovation.
Their combined backgrounds include drug discovery, translational research, clinical development, regulatory strategy, commercial operations, business development, diagnostics, global partnerships, organizational management, human resources, and executive leadership.
This diversity of experience reflects PeptiDream’s recognition that future success will depend not only on scientific innovation but also on operational excellence, strategic execution, and organizational development.
As biotechnology companies grow beyond early-stage research into later-stage clinical development and eventual commercialization, leadership with multidisciplinary expertise becomes increasingly important.
The appointments are therefore intended to complement PeptiDream’s existing scientific strengths while supporting the operational complexity associated with becoming a fully integrated global biopharmaceutical company.
Strengthening Organizational Structure
The executive appointments also form part of a broader organizational transformation currently underway at PeptiDream.
To support its continued growth, the company has been enhancing its internal governance and leadership structure by establishing several dedicated leadership teams designed to improve coordination across business functions.
In addition to its existing Research Leadership Team (RLT), which oversees scientific discovery activities, PeptiDream has created a Development Leadership Team (DLT) responsible for advancing clinical development programs.
The company has also established an Executive Leadership Team (ELT), which serves as the central leadership body responsible for aligning strategic priorities across research, development, operations, corporate functions, and business initiatives.
The creation of these leadership groups is intended to improve cross-functional collaboration, strengthen decision-making processes, enhance organizational agility, and support more efficient execution as the company’s operations continue expanding.
Positioning for Long-Term Growth
PeptiDream believes that strengthening its executive leadership team will help position the company for sustained long-term success as it advances an increasingly diverse clinical pipeline and expands its global footprint.
With growing research collaborations, advancing therapeutic programs, and increasing organizational complexity, experienced leadership will play a critical role in ensuring that scientific innovation is matched by strong operational execution.
The appointments of Catherine Ohura, Jun Kono, and Kodo Shikata represent an important investment in the company’s future. By adding accomplished leaders with proven track records across operations, strategy, commercialization, business development, and organizational leadership, PeptiDream aims to strengthen its ability to deliver innovative peptide-based medicines while continuing its transformation into a leading global discovery and development company.
As the organization enters its next phase of growth, these leadership additions are expected to enhance execution across the company’s expanding pipeline, improve operational efficiency, foster organizational excellence, and ultimately support PeptiDream’s mission of bringing innovative therapies to patients around the world while creating lasting value for partners, investors, and the broader healthcare community.